VERAPAMIL Drug Patent Profile
✉ Email this page to a colleague
When do Verapamil patents expire, and what generic alternatives are available?
Verapamil is a drug marketed by Mylan, Rising, Abraxis Pharm, Aspiro, Bedford, Eugia Pharma, Fresenius Kabi Usa, Gland, Heritage, Hospira, Intl Medication, Luitpold, Mankind Pharma, Marsam Pharms Llc, Smith And Nephew, Solopak, Zydus Pharms, Amneal, Caplin, Exela Pharma, Micro Labs, Nephron, Somerset, Somerset Theraps Llc, Apotex Corp, Cadila Pharms Ltd, Glenmark Pharms Ltd, Ivax Sub Teva Pharms, Pliva, Strides Pharma Intl, Sun Pharm Inds Inc, Zydus Lifesciences, Actavis Elizabeth, Chartwell Rx, Mutual Pharm, Sun Pharm Industries, Warner Chilcott, and Watson Labs. and is included in sixty-seven NDAs.
The generic ingredient in VERAPAMIL is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Verapamil
A generic version of VERAPAMIL was approved as verapamil hydrochloride by EXELA PHARMA on March 30th, 1984.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VERAPAMIL?
- What are the global sales for VERAPAMIL?
- What is Average Wholesale Price for VERAPAMIL?
Summary for VERAPAMIL
| US Patents: | 0 |
| Applicants: | 38 |
| NDAs: | 67 |
| Drug Prices: | Drug price information for VERAPAMIL |
| Drug Sales Revenues: | Drug sales revenues for VERAPAMIL |
| DailyMed Link: | VERAPAMIL at DailyMed |



